We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.84B
AUM Growth
+$214M
Cap. Flow
+$218M
Cap. Flow %
11.89%
Top 10 Hldgs %
45.79%
Holding
65
New
8
Increased
23
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$129M
2
KYMR icon
Kymera Therapeutics
KYMR
+$80.3M
3
CYTK icon
Cytokinetics
CYTK
+$77.7M
4
RVMD icon
Revolution Medicines
RVMD
+$36.1M
5
RPTX
Repare Therapeutics
RPTX
+$29.7M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$88.8M
2
ARGX icon
argenx
ARGX
+$53M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$38.2M
4
KURA icon
Kura Oncology
KURA
+$28.4M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.07B
$144M 7.84%
+3,378,380
New +$129M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$97.9M 5.33%
2,053,991
-232,900
-10% -$9.92M
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$94.3M 5.14%
3,064,734
+1,120,188
+58% +$29.7M
KYMR icon
4
Kymera Therapeutics
KYMR
$8.48B
$85M 4.63%
+2,630,658
New +$80.3M
XNCR icon
5
Xencor
XNCR
$1.5B
$80.2M 4.37%
2,068,098
– –
XOMA
6
DELISTED
Xoma
XOMA
$78.8M 4.29%
4,182,243
+156,086
+4% +$2.93M
RVMD icon
7
Revolution Medicines
RVMD
$39.9B
$73.1M 3.98%
2,101,049
+1,302,763
+163% +$36.1M
CYTK icon
8
Cytokinetics
CYTK
$10.6B
$71.9M 3.92%
+3,323,051
New +$77.7M
MRUS
9
DELISTED
Merus
MRUS
$67.7M 3.69%
5,645,571
+555,000
+11% +$7.17M
ACIU icon
10
AC Immune
ACIU
$226M
$47.9M 2.61%
9,818,758
-1,500,000
-13% -$10.8M
PTGX icon
11
Protagonist Therapeutics
PTGX
$8.74B
$46.4M 2.53%
2,372,288
+5,000
+0.2% +$93.8K
KURA icon
12
Kura Oncology
KURA
$794M
$45.6M 2.48%
1,489,112
-1,286,770
-46% -$28.4M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.94B
$45.5M 2.48%
3,066,797
+326,797
+12% +$3.83M
ARGX icon
14
argenx
ARGX
$53.6B
$44.5M 2.42%
169,600
-220,400
-57% -$53M
RCUS icon
15
Arcus Biosciences
RCUS
$3.49B
$44.5M 2.42%
2,597,222
+714,500
+38% +$16M
IMVT icon
16
Immunovant
IMVT
$7.86B
$42.2M 2.3%
1,198,427
+109,948
+10% +$3.31M
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.42B
$40.5M 2.21%
3,226,769
– –
REPL icon
18
Replimune Group
REPL
$887M
$38.9M 2.12%
1,691,834
-623,219
-27% -$14.2M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.08B
$38.7M 2.11%
3,499,346
-17,505
-0.5% -$206K
FBRX icon
20
Forte Biosciences
FBRX
$1.57B
$37.7M 2.05%
31,102
-8,052
-21% -$5.34M
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$37.6M 2.05%
8,009,353
+21,300
+0.3% +$108K
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.67B
$36.5M 1.99%
2,470,678
– –
IONS icon
23
Ionis Pharmaceuticals
IONS
$8.56B
$34.9M 1.9%
735,055
-687,787
-48% -$38.2M
STRO icon
24
Sutro Biopharma
STRO
$405M
$31M 1.69%
308,720
+71,881
+30% +$6.79M
ALXO icon
25
ALX Oncology
ALXO
$260M
$24.1M 1.31%
+638,928
New +$25.1M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2020 Portfolio in Review

As of Q3 2020, BVF Inc held 65 positions worth $1.84B, up 13% from $1.62B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2020, opening 8 new positions and adding to 23 existing holdings. Its largest new stake was Relay Therapeutics: 3,378,380 shares worth $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $53M trimmed.

  • BVF Inc's largest Q3 2020 buy was Relay Therapeutics: 3,378,380 shares worth $144M.
  • BVF Inc added most to Revolution Medicines in Q3 2020, an estimated $36.1M increase.
  • BVF Inc's biggest Q3 2020 reduction was argenx, cutting an estimated $53M.
  • BVF Inc fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $88.8M.
  • BVF Inc's ten largest holdings make up 46% of its $1.84B portfolio in Q3 2020.
  • BVF Inc opened 8 new positions and closed 3 in Q3 2020.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $1.84B.

Based on BVF Inc's 13F filing for Q3 2020, filed 13 Nov 2020.